The Use of Antifibrotic Recombinant nAG Protein in a Rat Liver Fibrosis Model.
Maha Mohamad ArafahMohammad M Al-QattanDurria A Abdulmaged-AhmedGhada A Al-NafesahNessrin Y JaduReginald S BagayawaMedhat K ShierAmir MarzoukHend S AlmalkiPublished in: BioMed research international (2019)
nAG treatment was able to significantly reduce the serum levels of several protein markers of liver fibrosis and also significantly reduced the histological degree of liver fibrosis.